Elucidating the mechanism of Live sex chat pic swap

2017 PCF Challenge Award (

2017 PCF Challenge Award ($1 Million) Award Donors: Steve Klinsky, Patrick Racz, Ted and Dani Virtue Principal Investigators: Michael Morris, MD (Memorial Sloan Kettering Cancer Center), Steven Larson, MD (Memorial Sloan Kettering Cancer Center), Jens Voortman, MD, Ph D (VUmc Cancer Center Amsterdam) Co-Investigators: Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mithat Gönen, Ph D (Memorial Sloan Kettering Cancer Center), Daniel Danila, MD (Memorial Sloan Kettering Cancer Center), Adriaan Lammertsma, Ph D (VUmc Cancer Center Amsterdam), Daniela Oprea-Lager, MD, Ph D (VUmc Cancer Center Amsterdam), Otto Hoekstra, MD, Ph D (VUmc Cancer Center Amsterdam), Gem Kramer, MD (VUmc Cancer Center Amsterdam) Project Title: Characterizing Mechanisms of Sensitivity and Resistance to Anti-Androgen Therapy with Whole-Body Molecular Imaging Description: What this means to patients: New molecular imaging methods have the potential to not only improve the detection of prostate cancer, but may act as predictive and prognostic biomarkers for treatment response and clinical outcomes.This team will evaluate two experimental PET imaging methods, F-18 PSMA and FDHT, for their prognostic value and clinical utility in patients with m CRPC undergoing treatment with AR-targeted therapy, and compare these with standard imaging methods and other promising biomarkers.Description: What this means to patients: New treatment strategies are needed for patients with hormone therapy-resistant prostate cancer. Mahajan and team will develop and optimize novel inhibitors of ACK1, a molecular pathway that regulates the androgen receptor, in preclinical studies.This may lead to a new prostate cancer treatment that is able to overcome resistance to AR-targeted therapies.2017 PCF Challenge Award ($1 Million) Award Donor: KBBO Group Principal Investigators: Ronald De Pinho, MD (The University of Texas MD Anderson Cancer Center), Yoaqi Alan Wang, Ph D (The University of Texas MD Anderson Cancer Center), Glen Traver Hart, Ph D (The University of Texas MD Anderson Cancer Center) Co-Investigators: Di Zhao, Ph D (The University of Texas MD Anderson Cancer Center) Project Title: Synthetic Essential Approach to Identify Novel Therapeutic Targets for Prostate Cancer Description: What this means to patients: The identification of novel ways to target prostate cancer is essential for improving treatments and outcomes for patients.This team will validate the potential for targeting CHD1 in PTEN-mutant prostate cancer alone or in combination with immunotherapy, and will identify other novel precision medicine drug targets that are effective against tumors with certain mutations.This team will profile mutations and genes expressed in prostate cancer samples from US Veterans throughout the course of clinical treatment to identify mechanisms and biomarkers of prostate cancer metastasis and treatment resistance.

||

2017 PCF Challenge Award ($1 Million) Award Donors: Steve Klinsky, Patrick Racz, Ted and Dani Virtue Principal Investigators: Michael Morris, MD (Memorial Sloan Kettering Cancer Center), Steven Larson, MD (Memorial Sloan Kettering Cancer Center), Jens Voortman, MD, Ph D (VUmc Cancer Center Amsterdam) Co-Investigators: Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mithat Gönen, Ph D (Memorial Sloan Kettering Cancer Center), Daniel Danila, MD (Memorial Sloan Kettering Cancer Center), Adriaan Lammertsma, Ph D (VUmc Cancer Center Amsterdam), Daniela Oprea-Lager, MD, Ph D (VUmc Cancer Center Amsterdam), Otto Hoekstra, MD, Ph D (VUmc Cancer Center Amsterdam), Gem Kramer, MD (VUmc Cancer Center Amsterdam) Project Title: Characterizing Mechanisms of Sensitivity and Resistance to Anti-Androgen Therapy with Whole-Body Molecular Imaging Description: What this means to patients: New molecular imaging methods have the potential to not only improve the detection of prostate cancer, but may act as predictive and prognostic biomarkers for treatment response and clinical outcomes.

This team will evaluate two experimental PET imaging methods, F-18 PSMA and FDHT, for their prognostic value and clinical utility in patients with m CRPC undergoing treatment with AR-targeted therapy, and compare these with standard imaging methods and other promising biomarkers.

Description: What this means to patients: New treatment strategies are needed for patients with hormone therapy-resistant prostate cancer. Mahajan and team will develop and optimize novel inhibitors of ACK1, a molecular pathway that regulates the androgen receptor, in preclinical studies.

This may lead to a new prostate cancer treatment that is able to overcome resistance to AR-targeted therapies.

Million) Award Donors: Steve Klinsky, Patrick Racz, Ted and Dani Virtue Principal Investigators: Michael Morris, MD (Memorial Sloan Kettering Cancer Center), Steven Larson, MD (Memorial Sloan Kettering Cancer Center), Jens Voortman, MD, Ph D (VUmc Cancer Center Amsterdam) Co-Investigators: Wassim Abida, MD, Ph D (Memorial Sloan Kettering Cancer Center), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mithat Gönen, Ph D (Memorial Sloan Kettering Cancer Center), Daniel Danila, MD (Memorial Sloan Kettering Cancer Center), Adriaan Lammertsma, Ph D (VUmc Cancer Center Amsterdam), Daniela Oprea-Lager, MD, Ph D (VUmc Cancer Center Amsterdam), Otto Hoekstra, MD, Ph D (VUmc Cancer Center Amsterdam), Gem Kramer, MD (VUmc Cancer Center Amsterdam) Project Title: Characterizing Mechanisms of Sensitivity and Resistance to Anti-Androgen Therapy with Whole-Body Molecular Imaging Description: What this means to patients: New molecular imaging methods have the potential to not only improve the detection of prostate cancer, but may act as predictive and prognostic biomarkers for treatment response and clinical outcomes.

This team will evaluate two experimental PET imaging methods, F-18 PSMA and FDHT, for their prognostic value and clinical utility in patients with m CRPC undergoing treatment with AR-targeted therapy, and compare these with standard imaging methods and other promising biomarkers.

Description: What this means to patients: New treatment strategies are needed for patients with hormone therapy-resistant prostate cancer. Mahajan and team will develop and optimize novel inhibitors of ACK1, a molecular pathway that regulates the androgen receptor, in preclinical studies.

This may lead to a new prostate cancer treatment that is able to overcome resistance to AR-targeted therapies.

elucidating the mechanism of-24elucidating the mechanism of-56elucidating the mechanism of-17

Lee Moffitt Cancer Center) Project Title: Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer.2017 PCF Challenge Award (

Lee Moffitt Cancer Center) Project Title: Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer.

2017 PCF Challenge Award ($1 Million) Award Donors: Lewis Ranieri, Steve Ross, Anonymous Donor Principal Investigators: Owen Witte, MD (University of California, Los Angeles) Co-Investigators: John Lee, MD, Ph D (University of California, Los Angeles), Stephen Forman, MD (City of Hope), Saul Priceman, Ph D (City of Hope) Project Title: CEACAM5-Directed Chimeric Antigen Receptor T Cell Therapy for Lethal Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is a highly aggressive and lethal subtype of prostate cancer for which treatments are urgently needed.

This team will develop a novel CAR T cell immunotherapy that selectively targets NEPC but not normal cells, and demonstrate its feasibility and safety in preclinical studies in preparation for clinical development.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

||

Lee Moffitt Cancer Center) Project Title: Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer.2017 PCF Challenge Award ($1 Million) Award Donors: Lewis Ranieri, Steve Ross, Anonymous Donor Principal Investigators: Owen Witte, MD (University of California, Los Angeles) Co-Investigators: John Lee, MD, Ph D (University of California, Los Angeles), Stephen Forman, MD (City of Hope), Saul Priceman, Ph D (City of Hope) Project Title: CEACAM5-Directed Chimeric Antigen Receptor T Cell Therapy for Lethal Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is a highly aggressive and lethal subtype of prostate cancer for which treatments are urgently needed.This team will develop a novel CAR T cell immunotherapy that selectively targets NEPC but not normal cells, and demonstrate its feasibility and safety in preclinical studies in preparation for clinical development.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

Million) Award Donors: Lewis Ranieri, Steve Ross, Anonymous Donor Principal Investigators: Owen Witte, MD (University of California, Los Angeles) Co-Investigators: John Lee, MD, Ph D (University of California, Los Angeles), Stephen Forman, MD (City of Hope), Saul Priceman, Ph D (City of Hope) Project Title: CEACAM5-Directed Chimeric Antigen Receptor T Cell Therapy for Lethal Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is a highly aggressive and lethal subtype of prostate cancer for which treatments are urgently needed.This team will develop a novel CAR T cell immunotherapy that selectively targets NEPC but not normal cells, and demonstrate its feasibility and safety in preclinical studies in preparation for clinical development.2017 Movember Foundation – PCF Challenge Award (

Lee Moffitt Cancer Center) Project Title: Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer.

2017 PCF Challenge Award ($1 Million) Award Donors: Lewis Ranieri, Steve Ross, Anonymous Donor Principal Investigators: Owen Witte, MD (University of California, Los Angeles) Co-Investigators: John Lee, MD, Ph D (University of California, Los Angeles), Stephen Forman, MD (City of Hope), Saul Priceman, Ph D (City of Hope) Project Title: CEACAM5-Directed Chimeric Antigen Receptor T Cell Therapy for Lethal Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is a highly aggressive and lethal subtype of prostate cancer for which treatments are urgently needed.

This team will develop a novel CAR T cell immunotherapy that selectively targets NEPC but not normal cells, and demonstrate its feasibility and safety in preclinical studies in preparation for clinical development.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

||

Lee Moffitt Cancer Center) Project Title: Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer.2017 PCF Challenge Award ($1 Million) Award Donors: Lewis Ranieri, Steve Ross, Anonymous Donor Principal Investigators: Owen Witte, MD (University of California, Los Angeles) Co-Investigators: John Lee, MD, Ph D (University of California, Los Angeles), Stephen Forman, MD (City of Hope), Saul Priceman, Ph D (City of Hope) Project Title: CEACAM5-Directed Chimeric Antigen Receptor T Cell Therapy for Lethal Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is a highly aggressive and lethal subtype of prostate cancer for which treatments are urgently needed.This team will develop a novel CAR T cell immunotherapy that selectively targets NEPC but not normal cells, and demonstrate its feasibility and safety in preclinical studies in preparation for clinical development.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award (

Lee Moffitt Cancer Center) Project Title: Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer.

2017 PCF Challenge Award ($1 Million) Award Donors: Lewis Ranieri, Steve Ross, Anonymous Donor Principal Investigators: Owen Witte, MD (University of California, Los Angeles) Co-Investigators: John Lee, MD, Ph D (University of California, Los Angeles), Stephen Forman, MD (City of Hope), Saul Priceman, Ph D (City of Hope) Project Title: CEACAM5-Directed Chimeric Antigen Receptor T Cell Therapy for Lethal Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is a highly aggressive and lethal subtype of prostate cancer for which treatments are urgently needed.

This team will develop a novel CAR T cell immunotherapy that selectively targets NEPC but not normal cells, and demonstrate its feasibility and safety in preclinical studies in preparation for clinical development.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

||

Lee Moffitt Cancer Center) Project Title: Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer.2017 PCF Challenge Award ($1 Million) Award Donors: Lewis Ranieri, Steve Ross, Anonymous Donor Principal Investigators: Owen Witte, MD (University of California, Los Angeles) Co-Investigators: John Lee, MD, Ph D (University of California, Los Angeles), Stephen Forman, MD (City of Hope), Saul Priceman, Ph D (City of Hope) Project Title: CEACAM5-Directed Chimeric Antigen Receptor T Cell Therapy for Lethal Neuroendocrine Prostate Cancer Description: What this means to patients: Neuroendocrine prostate cancer (NEPC) is a highly aggressive and lethal subtype of prostate cancer for which treatments are urgently needed.This team will develop a novel CAR T cell immunotherapy that selectively targets NEPC but not normal cells, and demonstrate its feasibility and safety in preclinical studies in preparation for clinical development.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, Ph D (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian) Co-Investigators: Kimberly Ku, MD (University of Wisconsin) Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate Description: What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.2017 Movember Foundation – PCF Challenge Award ($1 Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

Million) Principal Investigators: Chad Mirkin, Ph D (Northwestern University) Co-Investigators: Bin Zhang, MD, Ph D (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, Ph D (Northwestern University) Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer Description: What this means to patients: Therapies that effectively stimulate a person’s immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

Leave a Reply